



NAVANA PHARMA Navana Pharmaceuticals PLC.

Corporate Office:

House # 99, Road #04, Block # B, Banani, Dhaka-1213

PRICE SENSITIVE INFORMATION

This is for kind information to all valued shareholders of Navana Pharmaceuticals PLC. and stakeholders that the Board of Directors of the company in its 54th meeting held on 29th April, 2025 ended at 5.00 p.m. has considered and approved, among others, the Un-audited Financial Statements for the Third quarter (Q3) period ended on March 31, 2025 and took the following Price Sensitive Decision:-

Comparative Statement on Un-audited Financial Statement for the third quarter (Q3) financial year-2024-2025 period ended on March 31, 2025:

Sl. No	Particulars	01.07.2024-31.03.2025	01.07.2023-31.03.2024	01.01.2025-31.03.2025	01.01.2024-31.03.2024
I	Earnings Per Share (EPS)	3.49	3.09	1.01	1.00
ii	Net Operating Cash Flow Per Share (NOCFPS)	10.22	1.59	N/A	N/A
		As at 31.03.2025	As at 30.06.2024		
iii	Net Asset Value (NAV)	4,867,721,167	4,561,095,560	N/A	N/A
iv	Net Asset Value Per Share	45.32	42.46	N/A	N/A

Notes:

❖ Reasons of significant deviation in Earning Per Share (EPS) and Net Operating Cash Flows Per share (NOCFPS) between the periods:

- EPS: Increment of Earnings per Share in the reporting period by 12.94% because of growth of Sales Revenue as well as optimum cost management policy.
- NOCFPS: Net Operating Cash Flow per Share (NOCFPS) has increased to Tk. 10.22 from Tk. 1.59, due to cash received from the customers income was higher than the cash payment for operation in the reporting period.

- ❖ In compliance with the Dhaka & Chittagong Stock Exchange (Listing) Regulation, 2015, the company will publish the Un-audited Financial Statement for the third quarter (Q3) period ended on March 31, 2025 in two widely circulated daily newspapers (one in Bengali and otherone in English) and also in an online news portal. The Un-audited Financial Statements for the third quarter (Q3) in details will be available in the website (www.navanapharma.com) of the company.

Dated : April 29, 2025

By order of the Board
sd/-

Lorens Shamol Mollick FCS
Company Secretary